This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. S Search for Related Content Social Bookmarking                         What's this?

Voodoo medicine — cardiovascular trials jinxed in New Orleans

Dr Anthony Wierzbicki discusses highlights of the 56th Annual Scientific Session of American College of Cardiology held at Morial Conventions Centre in New Orleans March 24th—27th, 2007

Consultant Chemical Pathologist St Thomas Hospital Lambeth Palace Road London SE1 7EH, Anthony.Wierzbicki{at}kcl.ac.uk

References

• Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomised trial. J Am Coll Cardiol 2007; 49:1272-8.[Abstract/Free Full Text]
• Crouse JR, III, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-• risk individuals with subclinical atherosclerosis: the METEOR Trial.JAMA 2007;297:1344-53.[Abstract/Free Full Text]
• Sacks FM The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wierzbicki AS Have we forgotten the pivotal role of highdensity lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005; 21:299-306.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wierzbicki AS Lipid-altering agents: the future. Int J Clin Pract 2004;58:1063-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wierzbicki AS Low HDLcholesterol: Common and under-treated, but which drug to use? Int J Clin Pract 2006; 60:1149-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nissen SE, Tsunoda T., Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-300.[Abstract/Free Full Text]
• Wierzbicki AS FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006;60:442-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Keech A., Simes RJ, Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the E FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chapman MJ, Assmann G., Fruchart JC et al. Raising highdensity lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid -a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20:1253-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Forrester JS, Makkar R., Shah PK Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111: 1847-54.[Abstract/Free Full Text]
• Tardif JC, Cote G., Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72.[Abstract/Free Full Text]
• Tardif JC, Gregoire J., Schwartz L. et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8.[Abstract/Free Full Text]
• Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jackson G. Stable angina: two important trials-RITA-2 and ACIP( Asymptomatic Cardiac Ischaemia Pilot). Int J Clin Pract 1997;51:419-20.[Web of Science][Medline] [Order article via Infotrieve]
• Boden WE, O'rourke RA, Teo KK et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007; 350:1503-16.
• Henderson RA, Pocock SJ, Clayton TC et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-70.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 142-144 (2007)
DOI: 10.1177/14746514070070030801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. S Search for Related Content Social Bookmarking                         What's this?